- Champignon Brands is Obtaining the Substantial Supply of Psilocybin for its Ongoing TBI/PTSD Preclinical Studies at the University of Miami’s Miller School of Medicine
- Champignon’s Lead Investigator and Research Partner, Dr. Michael Hoffer Secured the Long-Term Supply of Psilocybin Under DEA Schedule 1 License
- Champignon’s New Psilocybin Source is the Same Organization That Supplied the Psychedelics Research Studies and Trials at Johns Hopkins and Yale University
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496) announced Wednesday it obtained a long-term supply of Psilocybin for the company’s ongoing TBI/PTSD-focused preclinical studies taking place at the University of Miami’s Miller School of Medicine. Champignon Brands is a leading human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine.
Champignon reported, the company’s research partner and lead investigator, Dr. Michael Hoffer, secured the sustainable supply of Psilocybin under a DEA schedule 1 license, which it will use for its ongoing Psilocybin-based therapeutics studies. With a stable supply of Psilocybin secured, the company can also ramp up the development of its Psychedelics clinical pipeline.
Champignon’s new source of Psilocybin is the same organization that supplied the psychedelics research studies and trials at Johns Hopkins and Yale University. Yale is currently conducting a phase 2 study of Psilocybin for Major Depressive Disorder (MDD). Johns Hopkins completed its randomized, double-blind trial of Psilocybin in cancer patients, which saw Psilocybin produce substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer.
Champignon’s 100%-owned subsidiary, Tassili Life Sciences, is conducting preclinical studies and eventually, human clinical trials to demonstrate the safety and efficacy of the combination of Psilocybin and Cannabidiol in treating mTBI with PTSD or stand-alone PTSD. The final results of the studies and future trials are expected in 2021.
The company’s preclinical studies are moving forward under a collaborative research agreement with the University of Miami’s Miller School of Medicine and its medical campus that includes over 500,000 sq ft of research space, as well as a state-of-the-art, 1.8 million sq ft, lab-ready research park.
“We hope to continue to make significant progress on our preclinical trial studying the effects of an oral combination of Psilocybin and CBD on mTBI associated with PTSD. Since mTBI associated with PTSD is a combination disorder that affects more than 10 million individuals per year and has no proven medical treatment, our novel combination of medicines could be a breakthrough in treating these indications,” said Dr. Michael Hoffer.
SHRM Stock Price Action & Chart
Shares of Champignon Brands’ CSE listed SHRM stock closed Wednesday’s trading session at $0.76 per share, up 5.6% on the day. The company’s U.S. OTC Markets listed SHRMF stock closed the day up 2.3% at $0.54. In Germany, Champignon’s Frankfurt Exchange-listed shares closed the trading day at $0.48 per share, up 2.13% on the session.
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.